Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Completion of the demerger of Haleon and share consolidation of GSK
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated